跳至主要内容
临床试验/IRCT20200112046089N1
IRCT20200112046089N1招募中3 期

Evaluation of the effect of Resveratrol on the effectiveness of antiviral drug regimen in patients with COVID-19

Ahvaz University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Polymerase chain reaction (PCR) confirmed infection with SARS CoV2
  • Lung involvement confirmed with chest imaging
  • Hospitalized with: Fever (axillar or oral temperature = 38.0 °centigrade(C) or =38.6°centigrade tympanic or rectal) or Respiratory rate >24/min Or Cough
  • Less than 8 days since illness onset
  • Willingness of study participant to accept random assignment to any treatment arm
  • Acceptance of non-participation in another study before the 28th day of the study

排除标准

  • Autoimmune diseases (lupus, MS, etc.)
  • Hepatic failure
  • Hepatit B and C
  • pregnant and lactating women

研究者

相似试验

Resveratrol in COVID19 | 临床试验